Kezar Life Sciences, Inc. (KZR)

Market Cap	35.94M
Revenue (ttm)	n/a
Net Income (ttm)	-83.74M
Shares Out	7.31M
EPS (ttm)	-11.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,842
Open	5.180
Previous Close	5.130
Day's Range	4.900 - 5.230
52-Week Range	4.900 - 9.300
Beta	0.49
Analysts	Hold
Price Target	9.00 (+82.93%)
Earnings Date	Mar 25, 2025

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR
• Website: https://www.kezarlifesciences.com

Analyst Forecast

According to 2 analysts, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9.0, which is an increase of 82.93% from the latest price.

Price Target

$9.0

(82.93% upside)

Analyst Consensus: Hold